Selank

also known as: TP-7, threonyl-lysyl-prolyl-arginyl-prolyl-glycyl-proline

A Russian-developed tuftsin analog approved for anxiety — produces benzodiazepine-like anxiolysis via GABAergic modulation without sedation, dependence, or withdrawal.

A 7-amino-acid synthetic peptide analog of tuftsin with C-terminal PGP extension for protease resistance, developed at the Institute of Molecular Genetics (Moscow) as a non-sedating anxiolytic that modulates GABAergic tone.

Mechanism of action

Modulates GABA-A receptor sensitivity and enkephalin degradation without directly binding the benzodiazepine site. Upregulates expression of genes involved in inflammation, immune response, and neurogenesis. Has demonstrated anxiolytic activity comparable to diazepam in rodent models without the sedation, tolerance, or withdrawal associated with benzodiazepines, and without the serotonin-mediated side effects of SSRIs.

Primary uses

Generalized anxiety disorder (Russian approval)
Adjustment disorders
Cognitive performance under stress
Research on non-benzodiazepine anxiolytic mechanisms

Typical dosing

400–900 mcg 2–3 times daily (intranasal)

Russian clinical dosing: 0.15% solution, 2–3 drops per nostril, 2–3 times daily for 10–14 days.

Regulatory status

Approved in Russia for generalized anxiety disorder and adjustment disorders. Not approved by the FDA or EMA.

References

[pubmed] Zozulya AA, et al. "Efficacy of novel selective anxiolytic Selank." Bull Exp Biol Med, 2008;146:694-695.
[pubmed] Medvedev VE, et al. "Optimization of therapy for patients with general anxiety disorder through the use of peptide anxiolytic Selank." Zh Nevrol Psikhiatr Im S S Korsakova, 2014;114:17-22.

Related peptides

Semax

A synthetic ACTH-derived heptapeptide approved in Russia for stroke rehabilitation and optic nerve disorders, with documented BDNF upregulation and broad nootropic activity.

Cerebrolysin

A porcine-derived neurotrophic peptide preparation approved in 40+ countries (not US) for stroke, dementia, and traumatic brain injury — with the largest clinical evidence base of any nootropic peptide preparation.

PE-22-28

A short peptide that selectively blocks the TREK-1 potassium channel — studied in animal models as a fast-acting antidepressant candidate.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.